How Regeneron, maker of a best-selling eye drug, is using patent tactics to try to thwart competition

Taking stock of the drug industry, from the lab to the medicine chest

July 10, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | How Regeneron, maker of a best-selling eye drug, is using patent tactics to try to thwart competition The battle over Eylea has focused interest on a pair of congressional bills that attempt to address how drug companies exploit the U.S. patent system. By Ed Silverman STAT+ | FDA publishes rejection letters sent to drugmakers, with a big caveat FDA's Marty Makary says release of rejection letters will help drugmakers and investors understand decisions behind denials. But there's a big caveat. By Andrew Joseph and Lizzy Lawrence STAT+ | Renasant Bio, an underdog in the race to develop kidney disease therapies, raises $54.5 million The company plans to develop two therapies for a common renal condition called autosomal dominant polycystic kidney disease, or ADPKD. By Allison DeAngelis Adobe STAT+ | Opinion: How to evaluate GLP-1s and Medicare costs? Here's one idea CMS should create a new value-based care payment pilot that would test coverage of GLP-1s on beneficiaries. By Soumi Saha and Somaieh McMullan

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser